Clearmind Medicine Inc.'s SEC filings document foreign private issuer reports for a clinical-stage biotech developing non-hallucinogenic, neuroplastogen-derived psychedelic therapeutics. Form 6-K reports furnish press releases on CMND-100, MEAI-based Alcohol Use Disorder clinical development, European patent activity for PTSD compounds, and communications tied to FDA regulatory pathways.
The filings also record capital-structure matters, including securities purchase agreements, convertible promissory notes, conversions into common shares and amendments to financing capacity. Governance disclosures cover board composition, committee assignments and Nasdaq independence determinations, while incorporated registration statements on Form F-3 and Form S-8 connect current reports to the company's securities registration record.
Clearmind Medicine Inc. files a Form F-3 to register for resale up to 22,626,988 common shares that are issued or issuable upon conversion of convertible promissory notes held by institutional investors (the CLA Investors). The registered shares are calculated assuming conversion of up to $10.0M principal plus $3.576M accrued interest at an assumed conversion price of $0.60 per share.
The company has received $8.15M in gross proceeds from Promissory Notes to date and may receive up to an additional $10.0M of gross proceeds under the SPAs. Conversion terms provide that the conversion price is the lower of a $40.40 fixed price or 88% of the 20-day VWAP, subject to a $0.60 Floor Price (amended). CLA Investor conversions are limited so no single CLA Investor exceeds 4.99% beneficial ownership following conversion.
Clearmind Medicine Inc. amended its previously announced securities purchase agreements for convertible promissory notes so that, as of April 30, 2026, $10,000,000 of capacity remains available for future issuances of these notes. This preserves access to additional financing through convertible debt instruments agreed with existing investors.
The company also reported governance changes. On April 26, 2026, board chair Amitay Weiss resigned, stating his departure did not arise from any disagreement with the company or its management. On April 27, 2026, the board appointed Hila Kiron-Revach as chairperson and added Asaf Itzhaik to the compensation and nominating and corporate governance committees. The audit, compensation, and nominating committees were reconstituted, and the board designated Kiron-Revach, Yehonatan Shachar, and Itzhaik as independent under Nasdaq listing rules.
Clearmind Medicine Inc. furnished a report describing its evaluation of lead candidate CMND-100 (MEAI) for potential U.S. FDA Breakthrough Therapy Designation to treat Alcohol Use Disorder. The company cites positive results so far from its ongoing FDA-approved Phase I/IIa clinical trial in this indication.
Clearmind develops non-hallucinogenic, second-generation neuroplastogen-derived therapeutics for under-treated conditions and holds a growing patent portfolio. The company stresses that it has not yet submitted a Breakthrough Therapy Designation request for MEAI and that the FDA has not granted any such designation.
Clearmind Medicine Inc. reports new activity under its previously announced convertible note financing and a rapid conversion into equity. The company agreed with its CLA Investors to issue and sell convertible promissory notes with an aggregate principal amount of $2,700,000, for a cash purchase price equal to 90% of principal, or $2,430,000. On April 21, 2026, the CLA Investors converted an aggregate of $2,680,029.60 under the notes into 4,466,716 common shares in accordance with the note terms.
Clearmind Medicine Inc. is drawing additional funding under previously announced securities purchase agreements. The company agreed with existing CLA Investors to issue and sell convertible promissory notes with an aggregate principal amount of $2,700,000. These notes will be purchased for cash equal to 90% of principal, or $2,430,000, and are part of a larger facility of up to $10,000,000 in convertible promissory notes. The transaction is expected to close on or about April 21, 2026, and this report is incorporated by reference into Clearmind’s existing Form F-3 and Form S-8 registration statements.
Clearmind Medicine Inc. filed a Form 6-K to furnish a press release responding to President Donald J. Trump’s Executive Order titled “Accelerating Medical Treatments for Serious Mental Illness,” which asks the FDA to prioritize review of certain psychedelic drugs designated as breakthrough therapies and to expand patient access pathways.
The company highlights that its proprietary compound MEAI (CMND-100) was previously named in bipartisan bill H.R. 7091 related to veterans’ access to emerging treatments, and that it is running FDA-approved Phase I/IIa clinical trials for CMND-100 in alcohol use disorder at Yale School of Medicine and Johns Hopkins University. Clearmind notes an intellectual property portfolio of nineteen patent families, including 31 granted patents, and states that the first paragraph of the press release is incorporated by reference into several existing Form F-3 and Form S-8 registration statements.
Clearmind Medicine, a clinical-stage biotech, reported a positive safety review from its independent Data and Safety Monitoring Board for its ongoing FDA-approved Phase I/IIa trial of CMND-100 in Alcohol Use Disorder.
The DSMB recommendation followed completion of the third patient cohort and was based on top-line safety data showing CMND-100 was well tolerated with no serious adverse events. This supports a favorable safety and tolerability profile seen in earlier cohorts.
The company will now advance to the fourth cohort and increase the CMND-100 dose to 160mg. The multinational, multicenter study evaluates safety, tolerability, pharmacokinetics and preliminary efficacy of this non-hallucinogenic, MEAI-based oral drug candidate in patients with moderate to severe Alcohol Use Disorder.
Clearmind Medicine Inc. reports updates to its convertible note financing with existing investors. The company agreed to issue and sell new convertible promissory notes with an aggregate principal of $1,750,000, for cash proceeds equal to 90% of principal, or $1,575,000.
The investors then converted $875,000 of these promissory notes into common shares at a fixed conversion price of $0.60 per share. Clearmind and the investors also amended the floor price in the promissory note form attached to the original securities purchase agreements to $0.60 per common share, setting a defined minimum conversion reference level.
Clearmind Medicine Inc. issued and sold convertible promissory notes with an aggregate principal amount of $1,750,000 to existing CLA investors under previously signed securities purchase agreements. The notes were sold for a cash purchase price equal to 90% of principal, providing $1,575,000 in proceeds on April 14, 2026.
The notes are part of a broader facility allowing issuance of up to $10,000,000 in aggregate principal amount of convertible promissory notes. This report is incorporated by reference into Clearmind’s existing Form F-3 and Form S-8 registration statements.
Clearmind Medicine Inc. reported that its oral drug candidate CMND-100, a non-hallucinogenic MEAI-based therapy for alcohol use disorder, met the primary safety and tolerability endpoint in an FDA-approved Phase I/IIa clinical trial.
Data from the trial’s third cohort showed CMND-100 was well tolerated at the highest dose tested so far, with no serious adverse events and a high safety profile consistent with earlier cohorts. The multinational, multicenter study is also assessing pharmacokinetics and preliminary efficacy in patients with moderate to severe alcohol use disorder. The company highlights this milestone as supporting continued development of CMND-100 as a potential novel treatment option.